MEIRAGTX HOLDINGS PLC
MGTX KYG596651029
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Annual Performance 1
2021 | 2022 | 2023 | 2024 | 2025 |
---|---|---|---|---|
53% | -72% | 8% | -17% | 2% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
Person | Price | Shares | Total | Published | Completed |
---|---|---|---|---|---|
Forbes Alexandria CEO |
8.39 USD |
47,500 Sold |
398,525 USD |
07/10/2025 | 07/10/2025 |
Giroux Richard CFO |
8.52 USD |
24,000 Sold |
204,480 USD |
22/07/2025 | 22/07/2025 |
Forbes Alexandria CEO |
7.97 USD |
47,500 Sold |
378,575 USD |
08/07/2025 | 08/07/2025 |
Giroux Richard CFO |
6.00 USD |
24,000 Sold |
144,000 USD |
22/04/2025 | 22/04/2025 |
Forbes Alexandria CEO |
5.34 USD |
47,500 Sold |
253,650 USD |
08/04/2025 | 08/04/2025 |
Giroux Richard CFO |
6.29 USD |
24,000 Sold |
150,960 USD |
21/01/2025 | 21/01/2025 |
Forbes Alexandria CEO |
6.30 USD |
11,661 Sold |
73,464 USD |
07/01/2025 | 08/01/2025 |
Forbes Alexandria CEO |
6.47 USD |
35,839 Sold |
231,878 USD |
07/01/2025 | 07/01/2025 |